Overview: HMB45 Immunohistochemistry TestIntroduction: The HMB45 Immunohistochemistry Test detects HMB45 protein to diagnose melanoma, causing skin lesions or discoloration. Aligned with 2023 NCCN guidelines, it uses immunohistochemistry for high specificity, supporting cancer screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in histopathology for patients with suspected melanoma.
Other Names: HMB45 IHC Assay, Melanoma IHC Test.
FDA Status: Laboratory-developed test (LDT), meeting histopathology standards for diagnostic accuracy.
Historical Milestone: HMB45 testing began in the 1980s with melanoma research. Immunohistochemistry-based methods improved in the 2000s, enhancing diagnostic precision.
Purpose: Detects HMB45 to diagnose melanoma, guides treatment, and evaluates patients with skin lesions or discoloration.
Test Parameters: 1. HMB45 Protein
Pretest Condition: No fasting required. Collect tissue via skin biopsy. Report history of skin lesions, discoloration, or sun exposure.
Specimen: 0.5-2 cma³ tissue (FFPE). Transport in a biohazard container.
Sample Stability at Room Temperature: 7 days
Sample Stability at Refrigeration: Not refrigerated
Sample Stability at Frozen: Not frozen
Medical History: Document skin lesions, discoloration, sun exposure, or family history of melanoma. Include current medications, especially immunotherapy.
Consent: Written consent required, detailing the tests purpose, cancer implications, and risks of biopsy.
Procedural Considerations: Uses immunohistochemistry to detect HMB45 in skin tissue. Results are available in 1-2 days, supporting rapid clinical decisions. Performed in laboratories, often for melanoma diagnosis.
Factors Affecting Result Accuracy: Improper tissue fixation or processing can affect results. Low tissue quality may reduce staining accuracy.
Clinical Significance: Positive HMB45 staining confirms melanoma, guiding surgery or immunotherapy. Negative staining may require further marker testing.
Specialist Consultation: Consult a dermatologist or oncologist for result interpretation and treatment planning.
Additional Supporting Tests: S100 IHC, Melan-A IHC, or PET-CT to confirm melanoma diagnosis.
Test Limitations: Not specific to melanoma; other melanocytic lesions may express HMB45. Clinical correlation is needed.
References: NCCN Melanoma Guidelines, 2023; American Journal of Surgical Pathology, Prieto VG, 2022.
